Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MTTP | P55157 | 3/20 | 0.43 |
| ▸ | APOB | P04114 | 2/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6491596 | 0.91 | NPC1 (0.53) | SMOTRPV1RUVBL1POLBGAA | |
| SCHEMBL6503248 | 0.91 | HTR2C (0.49) | SMOTRPV1RUVBL1GAAMTTP | |
| SCHEMBL7080705 | 0.89 | SMO (0.49) | SMOTRPV1POLBGAAMTTP | |
| SCHEMBL6793327 | 0.89 | SMO (0.59) | SMOTRPV1POLBGAAMTTP | |
| SCHEMBL6490835 | 0.86 | SMO (0.50) | SMOTRPV1MTTPAPOBNR3C1 | |
| SCHEMBL6487848 | 0.85 | SMO (0.46) | SMOTRPV1RUVBL1GAAMTTP | |
| SCHEMBL6488795 | 0.84 | SMO (0.50) | SMOTRPV1MTTPAPOBNR3C1 | |
| SCHEMBL6499284 | 0.84 | SMO (0.49) | SMOTRPV1GAAMTTPAPOB | |
| SCHEMBL6501945 | 0.83 | NPC1 (0.56) | POLBGAANPC1MAPTPKM | |
| SCHEMBL6502809 | 0.83 | L3MBTL1 (0.46) | SMONPC1MAPTPKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMO 2580/4885TRPV1 2245/4885RUVBL1 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.